Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Li HR;Li HR; Huang JJ; Guo HQ; Zhang X; Xie Y; Zhu HL; Zhai LZ; Pu XX; Huang Y; Guo CC; Lin TY
  • Source:
    Journal of viral hepatitis [J Viral Hepat] 2011 Dec; Vol. 18 (12), pp. 877-83. Date of Electronic Publication: 2010 Nov 05.
  • Publication Type:
    Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford ; Boston : Blackwell Scientific Publications, 1994-
    • Subject Terms:
      Antineoplastic Agents/*administration & dosage ; Antiviral Agents/*administration & dosage ; Guanine/*analogs & derivatives ; Hepatitis B/*prevention & control ; Lamivudine/*administration & dosage ; Lymphoma/*complications ; Lymphoma/*drug therapy; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Chemoprevention/methods ; China ; Female ; Guanine/administration & dosage ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Virus Activation/drug effects ; Young Adult
    • Abstract:
      During chemotherapy for lymphoma, the administration of cytotoxic agents and rituximab often results in hepatitis B reactivation (incidence, 14-72%). This study was designed to compare the efficacy of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients. Between January 2007 and February 2009, patients treated in four hospitals in China were screened to identify those most appropriate for analysis. These patients received either entecavir or lamivudine during chemotherapy and for 6 months after completion of chemotherapy. A total of 34 patients received entecavir and 89 patients received lamivudine. Compared with the lamivudine group, the entecavir group had significantly lower rates of hepatitis (5.9 vs 27.0%, P = 0.007), hepatitis B reactivation (0 vs 12.4%, P = 0.024) and disruption of chemotherapy (5.9 vs 20.2%, P = 0.042). All patients with hepatitis B reactivation had B-cell non-Hodgkin's lymphoma (stage III-IV). In lymphoma patients under chemotherapy treatment, entecavir is more effective than lamivudine in preventing hepatitis B reactivation. For patients with advanced stage disease, entecavir should be considered the primary preventive therapy.
      (© 2010 Blackwell Publishing Ltd.)
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Antiviral Agents)
      2T8Q726O95 (Lamivudine)
      5968Y6H45M (entecavir)
      5Z93L87A1R (Guanine)
    • Publication Date:
      Date Created: 20101109 Date Completed: 20120307 Latest Revision: 20220419
    • Publication Date:
      20231215
    • Accession Number:
      10.1111/j.1365-2893.2010.01386.x
    • Accession Number:
      21054683